Indexing
All Issues
Submission
Author Guidelines
Reviewers
Editorial Members
Publication Fee
Vol.1 , No. 5, Publication Date: Nov. 22, 2014, Page: 172-175
 for capsules. The results showed that all parameters of new formulations are in accordance with the BP/USP limits.&picture=http://www.aascit.org/aascit/decorators/img/journal/906.jpg)
| [1] | Shabana Naz Shah, Research Institute of Pharmaceutical Sciences, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Karachi, Karachi, Pakistan. |
| [2] | Waseem Shahzad, Research Institute of Pharmaceutical Sciences, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Karachi, Karachi, Pakistan. |
Olanzepine and fluoxetine HCl are used to treat the episodes of depression, in the present study manufactured the new combined formulations of Olanzepine and fluoxetine HCl by using Pregelatenized starch, Sodium lauryl sulphate, Aerosil-200 and Magnesium stearate. This study is divided into two phases. In the first phase of the study new formulation of Olanzepine and fluoxetine HCl capsules were prepared. In the 2nd phase of study new combined formulation is evaluated for their physical parameters like average weight, weight variation, disintegration time and also evaluated the chemical analysis like dissolution behaviour and assay. All quality control parameters: average weight, weight variation test, disintegration test, dissolution test and assay were carried out specified by BP/USP (British and United state Pharmacopoeia) for capsules. The results showed that all parameters of new formulations are in accordance with the BP/USP limits.
Keywords
Olanzepine and fluoxetine HCl, Formulations, Dissolution, Disintegration
Reference
| [01] | Shen WW, (1999) The Metabolism of Atypical Antipsychotic Drugs, An Update, Ann Clin Psychiatry, 11(3), 145-158. http://www.ncbi.nlm.nih.gov/pubmed/10482125 |
| [02] | Kapur S, Remington G, (2001) Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia, Annu Rev Med., 52, 503–517. http://www.uio.no/studier/emner/matnat/farmasi/FRM2410/v06/undervisningsmateriale/psykoser_behandling_artikler/atyipical_typical_antipsychotics.pdf |
| [03] | Moffat AC, Osselton MD, Widdop B, (2004) Clarke’s analysis of drugs and poisons, Pharmaceutical Press, London. |
| [04] | Labat L, Deveaux M, Dallet P, Dubost JP, (2002) Separation of new antidepressants and their metabolites by micellar electrokinetic capillary chromatography, J Chromatogr B, 773(1), 17–23. http://www.ncbi.nlm.nih.gov/pubmed/12015266 |
| [05] | Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, et al., (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis, The Lancet, 382(9896), 951–962. http://www.sciencedirect.com/science/article/pii/S0140673613607333 |
| [06] | Mueller TI, Leon AC, Keller MB, Solomon DA, Endicott J, Coryell W, Warshaw M, Maser JD, (1999) Recurrence after recovery from major depressive disorder during 15 years of observational follow-up, Am J Psychiatry, 156(7), 1000–1006. http://www.ncbi.nlm.nih.gov/pubmed/10401442 |
| [07] | Mann JJ, (2005) The medical management of depression, New Engl J Med, 353(17), 1819–1834. http://www.ncbi.nlm.nih.gov/pubmed/16251538 |
| [08] | Molina-Hernández M, Téllez-Alcántra NP, Oliveira-Lopez JI, Jaramillo MT, (2009) Olanzapine plus 17- estradiol produce antidepressant-like actions in rats forced to swim, Pharmacol Biochem Behav., 93, 491–497. |
| [09] | Nemeroff CB, (2007) The burden of severe depression: a review of diagnostic challenges and treatment alternatives, J Psychiatr Res., 41(3-4), 189–206. http://www.ncbi.nlm.nih.gov/pubmed/16870212 |
| [10] | Davis LL, Bartolucci A, Petty F, (2005) Divalproex in the treatment of bipolar depression: a placebo-controlled study, J Affect Disord., 85(3), 259–266. http://www.ncbi.nlm.nih.gov/pubmed/15780695 |
| [11] | Belmaker RH, (2004) Bipolar disorder, New Engl J Med., 351, 476–486. http://www.nejm.org/doi/full/10.1056/NEJMra035354 |
| [12] | Mario AC, Michael ET, (2014) Drug safety evaluation of olanzapine/fluoxetine combination, Expert Opinion on Drug Safety, 13(8), 1133-1141. doi:10.1517/14740338.2014.933804 |
| [13] | Corya SA, Andersen SW, Detke HC, Kelly LS, Campen LE, Sanger TM, Williamson DJ, Dube S, (2003) Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination, J Clin Psychiatry, 64(11), 1349–1356. http://www.ncbi.nlm.nih.gov/pubmed/14658950?ordinalpos=98&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum |
| [14] | Zhao C, Jain A, Hailemariam L, Suresh P, Akkisetty P, Joglekar G, Venkatasubramanian V, Reklaitis VG, Morris K, Basu P. (2006) Toward intelligent decision support for pharmaceutical product development, JPI., 1, 23–35. |
| [15] | http://www.usp.org/sites/default/files/usp_pdf/EN/USPNF/olanzapine_and_fluoxetine_capsules.pdf |
